Does Antiviral Therapy for Hepatitis B and C Prevent Hepatocellular Carcinoma?

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2010.06576.x/abstract;jsessionid=6F0396C1213662009755F710991CEEF3.d03t02>

Does Antiviral Therapy for Hepatitis B and C Prevent Hepatocellular
Carcinoma?

Anna Suk-Fong Lok MD, FRCPDOI: 10.1111/j.1440-1746.2010.06576.x

© 2010 Journal of Gastroenterology and Hepatology Foundation and
Blackwell Publishing Asia Pty Ltd
Issue

Journal of Gastroenterology and Hepatology
Accepted Article (Accepted, unedited articles published online for future
issues)

Abstract
Approximately 75% to 80% of hepatocellular carcinomas (HCC) worldwide are
attributed to chronic hepatitis B virus (HBV) and chronic hepatitis C
virus (HCV) infection. Thus, effective prevention of HBV and HCV infection
and progression from acute HBV and HCV infection to chronic hepatitis,
cirrhosis and HCC might prevent as many as 450,000 deaths from HCC each
year. The most effective approach to preventing HCC is to prevent HBV and
HCV infection through vaccination. Indeed HBV vaccine is the first vaccine
demonstrated to prevent cancers. However, a vaccine for HCV is not
available and for persons who are chronically infected with HBV or HCV,
antiviral therapy is the only option for preventing HCC. Direct evidence
supporting a benefit of antiviral therapy on the prevention of HCC has
been shown in a few randomized controlled trials. There is abundant
evidence that antiviral therapy, in patients with long-term virological
response, can improve liver histology providing indirect support that
antiviral therapy may prevent HCC by slowing progression of liver disease
and possibly even reversing liver damage. Nevertheless, the risk of HCC
remains in patients with chronic HBV or chronic HCV infection if treatment
is initiated after cirrhosis is established. These data indicate that
treatment might be of greater benefit if instituted earlier in the course
of chronic hepatitis B or C. Safer, more effective, and more affordable
antiviral therapies are needed for both hepatitis B and hepatitis C so
more patients can benefit from treatment and more HCCs can be prevented.

<http://onlinelibrary.wiley.com/d ... 10.06576.x/abstract;jsessionid=6F0396C1213662009755F710991CEEF3.d03t02>

[from Google translate - not 100% accurate][从谷歌翻译 - 不是100％准确]

是否B和C型肝炎的抗病毒治疗能预防肝癌
癌？

安娜锡芳乐博士FRCPDOI：10.1111/j.1440-1746.2010.06576.x

© 2010胃肠病学和肝病基金会
布莱克威尔出版亚洲私人有限公司
发行

胃肠病学和肝病
接受第（接受，为未来网上发表文章未经编辑
问题）

摘要
大约有75％至80％的肝细胞癌（HCC）的全世界
由于慢性乙型肝炎病毒（HBV）和慢性丙型肝炎
肝炎病毒（HCV）感染。因此，有效预防乙型肝炎和丙型肝炎病毒感染
急性乙型肝炎和丙型肝炎病毒感染和慢性肝炎的进展，
肝硬化和肝癌的预防肝癌的每个可能多达45万死亡
一年。最有效的办法来防止肝癌是预防HBV和
丙型肝炎病毒感染通过疫苗接种。事实上，乙肝疫苗疫苗是第
证明预防癌症。然而，丙型肝炎病毒疫苗没有
谁是现有的，对慢性乙型肝炎病毒或丙型肝炎病毒感染者，
抗病毒治疗是预防肝癌的唯一选择。直接证据
支持关于预防肝癌的抗病毒治疗的好处有
被证明在一些随机对照试验。有丰富的
证据表明，抗病毒治疗，与患者长期病毒学
对此，可以改善肝组织提供间接支持
抗病毒治疗可预防肝脏疾病进展减缓肝癌
甚至可能逆转肝损害。然而，肝癌风险
仍然在慢性HBV或慢性丙型肝炎病毒感染，如果治疗的病人
启动后肝硬化成立。这些数据表明，
治疗可能有更大受益，如果在课程中较早实行
慢性B或C型肝炎更安全，更有效，更实惠
抗病毒疗法需要为乙型肝炎和丙型肝炎等
更多的患者可以从治疗中获益，更可以预防肝癌。





(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc